Andreas Tiede: PK-Guided Approaches for Recombinant Porcine Factor VIII in Acquired Hemophilia
Andreas Tiede, Professor in the Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation at Hannover Medical School, shared a post on LinkedIn:
“Dosing of Obizur — recombinant porcine factor VIII — can be challenging due to short half-life in bleeding patients with acquired haemophilia. You can read about our experience with PK-guided continuous infusion and bolus dosing in an upcoming JTH article.”
Read the full article here .
Title: Pharmacokinetic strategies for achieving precise factor VIII control with susoctocog alfa in acquired hemophilia A
Authors: Justus Heeg, Christiane Dobbelstein, Alfonso Iorio, Heiko Schenk, Benjamin Seeliger, Andreas Tiede
Stay updated on the latest scientific advancements with Hemostasis Today.
-
Apr 10, 2026, 18:22Chris Hillis: Reflections on My Term as President of the Canadian Hematology Society
-
Apr 10, 2026, 17:59Michelle Leona Cecil: Representing Microhealth at The Coalition for Hemophilia B Annual Symposium
-
Apr 10, 2026, 17:47Lucie Raskin: Comparing VTE Risk in Hormonal Contraceptives at NTHC 2026
-
Apr 10, 2026, 17:39Diverse Voices But Shared Mission – Day 1 of EHC Youth Leadership Workshop
-
Apr 10, 2026, 17:30Make Your Mark at the World Stroke Congress 2026 – World Stroke Organization
-
Apr 10, 2026, 17:23Sofie Abels: Implications for Targeted Screening for Thrombophilia in Young Stroke Patients
-
Apr 10, 2026, 17:08Armghan Ans: 3 Questions Worth Sitting with If You Work in Stroke AI
-
Apr 10, 2026, 17:03William Wallace: Vitamin C Is More Than ”Immune Support”
-
Apr 10, 2026, 16:58Wolfgang Miesbach: Greater Symptom Burden in Women with Bleeding Disorders – Insights from Irish Data